After-Hours Stocks Movers 7/2: (DRL) (DO) Higher; (BIND) (SNX) Lower (more...)
BIND Therapeutics (NASDAQ: BIND) 15.8% LOWER; Amgen will not incorporate Accurin in its therapeutic payload. Amgen had an option to select a novel Accurin candidate for further development, and if Amgen failed to exercise its option, then BIND had the right to exercise an exclusive option to obtain a license from Amgen to develop, manufacture and commercialize Accurins.
Doral Financial Corporation (NYSE: DRL) 2.6% HIGHER; sees continued upside after gaining 75% intra-day after winning an appeal
Synnex Corp. (NYSE: SNX) 2.1% LOWER; reported Q2 EPS of $1.52, $0.16 better than the analyst estimate of $1.36. Revenue for the quarter